Login to Your Account



Basilea Completes Recruitment for Phase III AntiFungal Trial

By Catherine Shaffer
Staff Writer

Monday, December 17, 2012

Basilea Pharmaceutica AG, of Basel, Switzerland, completed recruiting patients for a Phase III pivotal trial of its antifungal agent, isavuconazole. With partner Astellas Pharma Inc., Basilea is studying safety and efficacy of once-daily isavuconazole compared to twice-daily voriconazole for up to 84 days of treatment in infections caused by Aspergillus or other filamentous fungi.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription